857395P
Avanti
GT-11
N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide, powder
Synonym(s):
C8-CPPC, C8-cyclopropenylceramide, GT-11 dihydroceramide desaturase inhibitor
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
Empirical Formula (Hill Notation):
C28H53NO3
CAS Number:
Molecular Weight:
451.73
UNSPSC Code:
12352211
NACRES:
NA.25
Recommended Products
Assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 1 mg (857395P-1mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 857395P
lipid type
bioactive lipids
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
CCCCCCCCCCCCCCC1=C(C1)[C@@H](O)[C@@H](NC(CCCCCCC)=O)CO
General description
GT-11 is also termed as C8-cyclopropenylceramide or C8-CPPC.
Biochem/physiol Actions
GT-11 is an inhibitor of dihydroceramides (DHCer) desaturase activity.
Packaging
5 mL Amber Glass Screw Cap Vial (857395P-1mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Storage Class Code
11 - Combustible Solids
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Bioactive sphingolipids: An overview on ceramide, ceramide 1-phosphate dihydroceramide, sphingosine, sphingosine 1-phosphate
Handbook of Neurochemistry and Molecular Neurobiology:Neural Lipids, 373-383 (2010)
Gemma Triola et al.
Molecular pharmacology, 66(6), 1671-1678 (2004-09-17)
Dihydroceramide desaturase catalyzes the conversion of the innocuous precursor dihydroceramide into a highly bioactive product ceramide. We studied the effect of N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11), the first inhibitor of this enzyme, in primary cultured cerebellar neurons. Although desaturase was efficiently inhibited (IC50
Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells
Shin K, et al.
Biomolecules & Therapeutics, 20(5), 470-470 (2012)
Pau Muñoz-Guardiola et al.
Autophagy, 17(6), 1349-1366 (2020-05-14)
ABTL0812 is a first-in-class small molecule with anti-cancer activity, which is currently in clinical evaluation in a phase 2 trial in patients with advanced endometrial and squamous non-small cell lung carcinoma (NCT03366480). Previously, we showed that ABTL0812 induces TRIB3 pseudokinase
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service